In the news release, Novocure(TM) to Present NovoTTF(TM) Therapy Data at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology, issued 29-May-2012 by Novocure

PORTSMOUTH, N.H., May 29, 2012 /PRNewswire/ -- Novocure(TM), a commercial stage private oncology company, announced today that data from pre-clinical and clinical studies evaluating NovoTTF(TM)

Radiation oncology researchers have revised the system used by doctors since the 1990s to determine the prognosis of people with glioblastoma, which is the most devastating of malignant brain tumors.

For the first time, scientists at Fred Hutchinson Cancer Research Center have transplanted brain cancer patients' own gene-modified blood stem cells in order to protect their bone marrow against the toxic side effects of chemotherapy.

As National Brain Tumor Awareness Month begins, the National Brain Tumor Society and Accelerate Brain Cancer Cure will rally staff, family members, patients and advocates to urge Members of Congress